13 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
AN INNOVATIVE CAUSAL THERAPY FOR ALLERGY: SAFE AND RAPID INDUCTION OF AN ANTI-INFLAMMATORY IMMUNE RESPONSE USING A MUTANT HYPOALLERGEN AND VITAMIN D3 (BM4SIT)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
Allergy is the most prevalent chronic inflammatory disease, having great socio-economic impact. Chronic lifelong dependency on symptomatic drugs is an expensive reality for the vast majority of allergy sufferers. Allergen-specific immunotherapy is the only causal and effective treatment targeting the underlying immune mechanism in a more cost-effective way. Yet, long treatment duration and risk of ...
Voir le projet
10
Participants partenaires
TERMINÉ
Academia-Industry Research and Development Opportunities for Picornaviruses (AIROPico)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2017,
Viruses belonging to the large family of Picornaviridae such as enteroviruses, rhinoviruses and parechoviruses represent the most commonly encountered infectious agents in mankind. Several research groups in Europe are active on different aspects of picornavirus research. Nevertheless, prevalence, transmission, and pathogenesis are still largely unknown and no therapy is available for picorna infe ...
Voir le projet
10
Participants partenaires
TERMINÉ
Pathogen COinfection: HIV, Tuberculosis, Malaria and Hepatitis C virus (PathCO)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
Acquired immune deficiency (AIDS), tuberculosis (TB) and malaria are the primary infectious diseases causing death world wide. In addition to these pathogens, 170 million people are infected with hepatitis C virus (HCV), which leads to chronic liver disease. Because of shared routes of transmission, HCV co-infection is recognized as a major cause of morbidity and mortality among HIV-1 infected per ...
Voir le projet
11
Participants partenaires
TERMINÉ
Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation (BIO-DrIM)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. H ...
Voir le projet
17
Participants partenaires
TERMINÉ
Integrated Approaches to Food Allergen and Allergy Risk Management (IFAAM)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
Up to 20 million European citizens suffer from food allergy. However management of both food allergy (by patients and health practitioners) and allergens (by industry) is thwarted by lack of evidence to either prevent food allergy developing or protect adequately those who are already allergic. iFAAM will develop evidence-based approaches and tools for MANAGEMENT of ALLERGENS in FOOD and integrate ...
Voir le projet
46
Participants partenaires
TERMINÉ
"From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" (BRAINVECTORS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
"BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression.Although AAV, CAV and LVV are considered acc ...
Voir le projet
12
Participants partenaires
TERMINÉ
Biofilm Alliance (BALI)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,
Infections by biofilm-forming microorganisms on indwelling medical devices such as catheters, prosthetic joints and internal fracture fixation devices pose a serious health threat. Overall, approximately 3% of all patients receiving such devices develop biofilm infections, with costs adding up to billions of Euro’s.Current strategies to combat biofilms are based on conventional antibiotics. They o ...
Voir le projet
9
Participants partenaires
TERMINÉ
Translational Training network on the Cellular and Molecular Bases of Heart Homeostasis and Repair (CardioNeT)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
The CardioNeT Initial Training Network aims to implement a highly multidisciplinary, intersectoral and competitive training programme in cardiovascular research through cutting-edge projects and extensive training in complementary areas.CardioNeT training comprises two tightly linked components - research and complementary training - that will be implemented at local as well as network level and ...
Voir le projet
13
Participants partenaires
TERMINÉ
Type 2 diabetes and obesity among sub-Saharan African native and migrant populations: dissection of environment and endogenous predisposition (RODAM)
Date du début: 1 janv. 2012, Date de fin: 30 sept. 2015,
"Migration from Sub-Saharan Africa (SSA) to Europe is increasing. The limited evidence suggests that the risk of type 2 diabetes (T2D) and obesity among SSA migrants is higher than among their SSA peers living in Africa and European host populations. The reasons for these observations are only poorly understood, but may involve migration-related changes in lifestyle, genetic predisposition as well ...
Voir le projet
9
Participants partenaires
TERMINÉ
Generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions (HIVINNOV)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2015,
Highly active antiretroviral therapy is effective at controlling HIV-1 replication, however emergence and transmission of drug-resistant viruses is increasing, including viruses resistant to the newly developped integrase catalytic inhibitors. It is essential that new antiretrovirals (ARVs) become available. Most ARVs in development belong to the classes of viral enzyme inhibitors. Since HIV requi ...
Voir le projet
7
Participants partenaires
TERMINÉ
Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance (OVER-MYR)
Date du début: 1 janv. 2012, Date de fin: 30 juin 2015,
Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and c ...
Voir le projet
11
Participants partenaires
TERMINÉ
Breast Cancer Somatic Genetics Study (BASIS)
Date du début: 1 juil. 2010, Date de fin: 31 déc. 2014,
"All cancers arise due to somatically acquired mutations in their genomes which alter the function of key cancer genes. Understanding these critical mutational events underlying cancer development is paramount for advancing prevention, early detection, monitoring and treatment of the disease. Breast cancer is the most common class of cancer diagnosed in women worldwide with more than one million c ...
Voir le projet
16
Participants partenaires
TERMINÉ
Pathways common to brain development and ageing: defining strategies for preventive therapy and diagnostics (DEVELAGE)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,
"The increasing number of elderly people will have a major impact on the prevalence of age-related diseases, which will pose major challenges to keep health systems in Europe sustainable. Current knowledge is insufficient to identify the transition of normal brain ageing into Alzheimer`s Disease (AD)-like brain damage. Elucidation of the genes and pathways contributing to the earliest stages of AD ...
Voir le projet